Loading
The GM-CSF receptor is what sargramostim switches on to speed the recovery of white cells after leukaemia chemotherapy and stem cell transplantation, and it is the signal that tumour vaccines such as talimogene use to recruit immune cells.
The granulocyte-macrophage colony-stimulating factor receptor is made of a ligand-binding alpha chain (CSF2RA) and the common beta chain shared with the IL-3 and IL-5 receptors. Recombinant GM-CSF (sargramostim, Leukine) is approved to shorten neutrophil recovery after induction chemotherapy for acute myeloid leukaemia and after autologous and allogeneic stem cell transplantation, and to mobilise stem cells. GM-CSF is also encoded into talimogene laherparepvec and several cancer vaccines to attract and mature dendritic cells at the tumour site, while the receptor itself is a marker on juvenile myelomonocytic leukaemia cells.
In plain words · The GM-CSF receptor is what sargramostim switches on to speed the recovery of white cells after leukaemia chemotherapy and stem cell transplantation, and it is the signal that tumour vaccines such as talimogene use to recruit immune cells.
The GM-CSF receptor is what sargramostim switches on to speed the recovery of white cells after leukaemia chemotherapy and stem cell transplantation, and it is the signal that tumour vaccines such as talimogene use to recruit immune cells.
A type I cytokine receptor whose beta chain activates JAK2 and STAT5; it drives proliferation and differentiation of granulocyte and macrophage precursors and activates dendritic cells.
1 product aims at GM-CSF receptor (CSF2RA): other agents. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
Lineage antigen shared with normal dendritic cells and granulocytes and monocytes: HPA blood lineage group enriched at or above 25 nTPM, and surface-antigen class aim at it, so normal cells of the lineage are hit too. HPA CSF2RA: RNA tissue enhanced (placenta 60 nTPM); blood lineage group enriched (dendritic cells 170 nTPM, granulocytes 320 nTPM, monocytes 161 nTPM); no normal tissue stained high; highest cancer staining melanoma (3 of 12 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Leukaemia, Skin cancer (all types)); approvals of single-target medicines aimed at it also list Lymphoma, not counted; Open Targets associates it with 1 specific cancer type at or above 0.5 (acute myeloid leukemia). (Rule 5 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas CSF2RA tissue; Human Protein Atlas CSF2RA pathology; Open Targets ENSG00000198223 associations
First described 1989. Earliest sequence paper UniProt cites for the protein: Gearing D.P. et al, EMBO J, 1989, "Expression cloning of a receptor for human granulocyte-macrophage colony-stimulating factor". Source.
A type I cytokine receptor whose beta chain activates JAK2 and STAT5; it drives proliferation and differentiation of granulocyte and macrophage precursors and activates dendritic cells.
RNA: tissue enhanced (placenta 60 nTPM), detected in many normal tissues. Blood: group enriched (dendritic cells 170 nTPM, granulocytes 320 nTPM, monocytes 161 nTPM).
No normal tissue stained high.
HPA CSF2RA tissue · HPA CSF2RA pathology · HPA protein class: CD markers, FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Metastatic cancer | host% | Host target: GM-CSF receptor on white-cell precursors. Not a tumour alteration, so no prevalence applies; the drug acts on normal tissue or on symptoms. |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Sargramostim is a lab-made version of GM-CSF, the signal that tells bone marrow to make white cells; approved in 1991, it shortens the dangerous low-count period after leukaemia chemotherapy and stem cell transplants.
Query for this target: (TITLE:"GM-CSF receptor" OR ABSTRACT:"GM-CSF receptor" OR TITLE:"CSF2RA" OR ABSTRACT:"CSF2RA") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GM-CSF receptor (CSF2RA), not a curated reading list.
Shares Sargramostim, Talimogene laherparepvec, Melanoma.
Shares Talimogene laherparepvec, Melanoma.
Shares Talimogene laherparepvec, Melanoma.
Shares Talimogene laherparepvec, Melanoma.
Shares Sargramostim, Acute myeloid leukaemia.
Shares Talimogene laherparepvec, Melanoma.
Shares Talimogene laherparepvec, Melanoma.
Shares Talimogene laherparepvec, Melanoma.